Clinical trials: Shock
Hypotension, Shock
Optimal VAsopressor titraTION Pilot Randomized Controlled Trial
The purpose of this research study is to determine if it is better to give vasopressors to patients to maintain a higher blood pressure target versus a lower blood pressure target.
- Trial name
- OVATION (NCT01800877)
- Testing
- Vasopressors
- Where
- 10 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Francois Lamontagne
Achilles Tendinopathy
Ultrasound-Monitored Changes in Achilles Tendinopathy After Extracorporeal Shock Wave Therapy
This study is designed as a randomized, placebo-controlled clinical trial in which we monitor the effects of low-energy focused extracorporeal shockwave therapy (ESWT) in patients with Achilles tendinopathy (AT).
- Trial name
- NCT04780919
- Testing
- BTL-6000 FSWT
- Where
- Czechia
- Volunteers
- 18 people
- Sponsor
- University Hospital, Motol
Shock, Traumatic
Hypertonic Resuscitation Following Traumatic Injury
The purpose of this study is to determine if hypertonic saline with and without dextran can improve overall survival in victims of trauma with shock.
- Trial name
- NCT00316017
- Testing
- 7.5% hypertonic saline/6% Dextran-70 (HSD), 7.5% hypertonic saline (HS), 0.9% normal saline
- Where
- 10 sites in United States, Canada
- Volunteers
- 895 people
- Sponsor
- University of Washington
Trauma, Hemorrhage
Cold Stored Platelet in Hemorrhagic Shock
The Cold Stored Platelet Early Intervention in Hemorrhagic Shock (CriSP-HS) trial is a proposed 3 year, open label, multi-center, randomized trial designed to determine the feasibility, efficacy, and safety of urgent release cold…
- Trial name
- CriSP-HS (NCT04667468)
- Testing
- Cold Stored Platelets (CSP), Standard Care
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Jason Sperry
Treatment of Hypovolemia and Shock
Gelatines in Pediatric PatientS
The aim of volume replacement is to compensate a reduction in the intravascular volume e.g. during surgery and to counteract hypovolemia in order to maintain hemodynamics and vital functions.
- Trial name
- GPS (NCT02495285)
- Testing
- Gelofusine 4%, Gelaspan 4%
- Where
- 11 sites in Bulgaria, Germany and 3 more
- Volunteers
- 601 people
- Sponsor
- B. Braun Melsungen AG
Shock
Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study
Approximately 20,000 children per year in North America present to the hospital with severe shock. Children who develop this condition have very low blood pressures and as a result may suffer damage to their internal organs and…
- Trial name
- STRIPES (NCT02044159)
- Testing
- Hydrocortisone
- Where
- 7 sites in Canada
- Volunteers
- 57 people
- Sponsor
- Children's Hospital of Eastern Ontario
Pediatric Sepsis-induced MODS
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
This study is an open-label, multi-center, interventional trial in which children with sepsis-induced MODS undergo surveillance immune function testing beginning on Day 2 of MODS.
- Trial name
- GRACE (NCT03769844)
- Testing
- GM-CSF
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Nationwide Children's Hospital
Blunt Trauma, Penetrating Wound
Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma
Primary Aim: To determine the feasibility and safety of hypotensive resuscitation for the early treatment of patients with traumatic shock compared to standard fluid resuscitation.
- Conditions
- Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
- Trial name
- HypoResus (NCT01411852)
- Testing
- 0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus
- Where
- 6 sites in United States, Canada
- Volunteers
- 192 people
- Sponsor
- University of Washington
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality.
- Conditions
- Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
- Trial name
- NCT03518203
- Testing
- Eculizumab
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Severe Sepsis, Septic Shock
Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
The purpose of this study is to evaluate the pharmacokinetics of pioglitazone and to determine the effect on inflammatory biomarkers for pioglitazone in patients with severe sepsis and septic shock.
- Trial name
- NCT01352182
- Testing
- Pioglitazone hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cytokine Release Syndrome
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
"The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning…
- Trial name
- NCT04071366
- Testing
- Itacitinib, Immune effector cell therapy, Yescarta
- Where
- 10 sites in United States
- Volunteers
- 112 people
- Sponsor
- Incyte Corporation
Shock, Septic
COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2
The study objective is to clarify whether the application of high doses CPFA (coupled plasma-filtration adsorption) in addition to the current clinical practice is able to reduce hospital mortality in septic shock patients in…
- Trial name
- COMPACT-2 (NCT01639664)
- Testing
- High doses CPFA
- Where
- 13 sites in Italy
- Volunteers
- 115 people
- Sponsor
- Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Hemorrhagic Shock
Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock
The purpose of the study is to evaluate whether remote ischemic conditioning is a safe and effective intervention to prevent the development of inflammation and coagulopathy in trauma patients with hemorrhagic shock.
- Trial name
- NCT02071290
- Testing
- Pneumatic tourniquet
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Unity Health Toronto
Sepsis
Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis
The purpose of this study is to determine whether inhaled nitric oxide is an effective treatment for microcirculatory dysfunction and acute organ system failure in the early stage of sepsis therapy.
- Trial name
- NCT00608322
- Testing
- Inhaled nitric oxide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Institute of General Medical Sciences (NIGMS)
Cytokine Release Syndrome, COVID19
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
This protocol will evaluate the efficacy of Therapeutic Plasma Exchange (TPE) alone or in combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine release syndrome (CRS).
- Trial name
- NCT04374149
- Testing
- Therapeutic Plasma Exchange, Ruxolitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Prisma Health-Upstate
Severe Hepatic Veno-Occlusive Disease
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of…
- Trial name
- NCT00358501
- Testing
- Defibrotide
- Where
- 25 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
Shock, Septic
Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study
The objective of this pilot study is to assess overall feasibility prior to embarking on a larger randomized pragmatic trial comparing the clinical effectiveness of fluid resuscitation with NS versus LR for pediatric patients…
- Trial name
- PRoMPT BOLUS (NCT03340805)
- Testing
- Lactated Ringer, Normal saline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Philadelphia
Shock, Hemorrhagic, Injury Penetrating
Feasibility of Evaluating XSTAT Use in the Prehospital Setting
This study evaluates the prehospital use of the XSTAT device to control bleeding in junctional wounds. Participants will be randomized to the use of XSTAT versus standard care.
- Conditions
- Shock, Hemorrhagic, Injury Penetrating, Hemorrhage
- Trial name
- PhoXSTAT (NCT04663087)
- Testing
- XSTAT, Standard of Care
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham